Considering the up-regulation effect of TNF-a on IL6 and up-regulation effect of IL-6 on CRP, the similarity of results concerning CRP, IL-6 and TNF-a strengthened the persuasion of our study. In addition, the large number of included studies and large sample size also make our results more plausible. Our study also had several limitations. Firstly, a risk of bias was observed in several studies included in the present meta-analysis. But results from our sensitivity analysis showed that these biases did not have a significant influence on the pooled effect size. Secondly, a significant heterogeneity was observed in the three meta-analyses assessing the effect of marine-derived n-3 PUFAs supplementation on CRP, IL-6 and TNF-a in subjects with chronic non-autoimmune disease as well as the meta-analysis evaluating the effect of marine-derived n-3 PUFAs supplementation on IL-6 in healthy subjects. However, the sources of heterogeneity and their influence on the effect size were well explained by subgroup meta-analysis, meta-regression and restricted cubic spline analysis. Our findings provide a scientific guide for nutritional therapy of inflammation-related chronic diseases. Consecutive long-term supplementation of marine-derived n-3 PUFAs is recommended. Our present studies also suggest that marine-derived n-3 PUFAs supplementation can effectively prevent inflammation-related chronic diseases considering its significant lowering effect on CRP, IL-6 and TNF-a in healthy subjects. The anti-inflammatory effect tends to be the most effective in non-obese subjects. In conclusion, marine-derived n-3 PUFAs supplementation has a significant lowering effect on fasting blood level of TNF-a, IL-6 and CRP. It has since been Notoginsenoside-R1 confirmed to be a tick -borne flavivirus with close similarity with the Kyasanur Forest disease virus found in India. Other tick borne flaviviruses include Omsk Hemorrhagic fever virus and Tick-borne encephalitis viruses although AHFV is the first Evodiamine tickborne flavivirus linked to laboratory confirmed clinical illness in the Arabian Peninsula. Initially, the clinical disease caused by AHFV did not receive much attention and its epidemiology was not well comprehended: one early publication on clinical cases not only failed to consider the notorious cross reacting properties of flavivirus antibodies in patients recovering from flavivirus infections but also misinterpreted lack of tick bite histories as evidence against AHFV being tick borne and over-interpreted mosquito bite histories to suggest that the virus was mosquito-borne. These 2 patients were tested and found to have cross reactive antibodies to both West Nile fever and DEN viruses. This report renews the discourse as regards the origin of AHFV as well as other tick borne flaviviruses : Previously published molecular data has indicated tick borne flaviviruses originated from Africa. However, it is important to increase awareness and effective surveillance to detect cases of AHFV infection in geographically diverse areas of the world. Thus a regular review of all confirmed AHFV infections will enrich the scientific literature of the epidemiology of the disease its causes. The findings in this study have shown that Alkhurma hemorrhagic fever is steadily on the increase in Saudi Arabia and is gradually being reported beyond the geographic locality where it was originally discovered. This corroborates similar findings reported in the literature and this may indicate that the virus is being discovered outside of the area where the initial disease was described. It could also be that there is an increase in awareness of the disease, surveillance and improved laboratory diagnostic capabilities elsewhere.